

Margaret K Callahan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6743773/publications.pdf>

Version: 2024-02-01

63
papers

22,817
citations

126907

33
h-index

189892

50
g-index

65
all docs

65
docs citations

65
times ranked

29229
citing authors

#	ARTICLE	IF	CITATIONS
1	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
2	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research, 2022, 10, 303-313.	3.4	1
3	Fundamental immune“oncogenicity trade-offs define driver mutation“fitness. Nature, 2022, 606, 172-179.	27.8	23
4	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
5	Apples and Oranges? Considerations for EHR-Based Analyses Aggregating Data From Interventional Clinical Trials and Point-of-Care Encounters in Oncology. JCO Clinical Cancer Informatics, 2021, 5, 21-23.	2.1	0
6	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nature Medicine, 2021, 27, 1646-1654.	30.7	65
7	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
8	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	12.4	54
9	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	7.0	25
10	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
11	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	1.5	39
12	Clinical implications of drug“induced liver injury in early“phase oncology clinical trials. Cancer, 2020, 126, 4967-4974.	4.1	6
13	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	30.5	684
14	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine, 2020, 26, 1114-1124.	30.7	216
15	Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecologic Oncology, 2020, 158, 303-308.	1.4	4
16	<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. JCO Precision Oncology, 2020, 4, 665-679.	3.0	29
17	Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?. Cancer Cell, 2019, 36, 215-217.	16.8	29
18	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. Oncologist, 2019, 24, e196-e197.	3.7	31

#	ARTICLE	IF	CITATIONS
19	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. <i>Gynecologic Oncology</i> , 2019, 152, 251-258.	1.4	33
20	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	16.8	827
21	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	16.8	725
22	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	7.1	125
23	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	1.6	156
24	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. <i>Journal of Clinical Oncology</i> , 2018, 36, 1685-1694.	1.6	399
25	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw260.	6.3	56
26	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
27	Initial efficacy of anti-lymphocyte activation gene-3 (anti- LAG-3 ; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti- PD-1/PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9520-9520.	1.6	188
28	Immune Checkpoint Therapy in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 73-80.	2.0	10
29	Reply to A. Indini et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1018-1019.	1.6	0
30	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016, 38, 1310-1317.	2.0	65
31	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016, 44, 1069-1078.	14.3	418
32	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598.	10.7	594
33	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 165-202.	0.4	30
34	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016, 21, 848-854.	3.7	154
35	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 231-250.	0.5	36
36	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. <i>Nature Communications</i> , 2016, 7, 10391.	12.8	784

#	ARTICLE	IF	CITATIONS
37	Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. <i>Seminars in Oncology</i> , 2015, 42, 573-586.	2.2	21
38	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	27.0	6,773
39	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015, 7, 280sr1.	12.4	134
40	Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015, 33, 3454-3458.	1.6	24
41	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	1.6	892
42	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. <i>Cancer Immunology Research</i> , 2014, 2, 70-79.	3.4	100
43	Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. <i>Science Translational Medicine</i> , 2014, 6, 230ra45.	12.4	526
44	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. <i>Frontiers in Oncology</i> , 2014, 4, 385.	2.8	175
45	Oncogene Addiction: How Cells Handle the Habit. <i>Science Translational Medicine</i> , 2014, 6, .	12.4	0
46	Seeking Harmony Among Cancer Killers. <i>Science Translational Medicine</i> , 2014, 6, .	12.4	0
47	Nivolumab plus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 122-133.	27.0	3,776
48	Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions. <i>Current Oncology Reports</i> , 2013, 15, 500-508.	4.0	20
49	Immunomodulatory therapy for melanoma: Ipilimumab and beyond. <i>Clinics in Dermatology</i> , 2013, 31, 191-199.	1.6	57
50	Hepatotoxicity with Combination of Vemurafenib and Ipilimumab. <i>New England Journal of Medicine</i> , 2013, 368, 1365-1366.	27.0	655
51	Two Drugs Are Better than One—Modeling Drug Combinations in Cancer Therapy. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	3
52	Gut Reaction: Microbiome Provides a Clue to Gender Bias in Autoimmunity. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
53	Uncovering a Hidden Talent. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
54	T Cells Take Notice of Distinct Mutations in Cancer Cells. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0

#	ARTICLE	IF	CITATIONS
55	New MEK-inhibitors for Targeted Therapies. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
56	EGFR Mutations Transform Tumors Inside and Out. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
57	Searching for Needles in the T Cell Receptor Haystack. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
58	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. <i>New England Journal of Medicine</i> , 2012, 367, 2316-2321.	27.0	222
59	The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?. <i>Clinical Cancer Research</i> , 2012, 18, 1821-1823.	7.0	27
60	Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. <i>New England Journal of Medicine</i> , 2012, 366, 925-931.	27.0	1,836
61	Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8575-8575.	1.6	16
62	Implanted Hepatic Arterial Infusion Pumps. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 142-149.	2.0	12
63	Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy. <i>Seminars in Oncology</i> , 2010, 37, 473-484.	2.2	208